Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intravenous therapy for chronic heart failure exacerbations.

T Taneja1, M R Johnson, M Gheorghiade

  • 1Department of Medicine, Division of Cardiology, Northwestern University Medical School, Chicago, IL 60611.

Congestive Heart Failure (Greenwich, Conn.)
|August 22, 2002
PubMed
Summary

Chronic heart failure (HF) management has advanced, but hospitalizations for HF exacerbations remain high. Current intravenous therapies lack robust evidence from placebo-controlled trials, indicating a need for better treatment strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human labour is associated with altered regulatory T cell function and maternal immune activation.

Clinical and experimental immunology·2019
Same author

Maternal and fetal outcomes in pregnancies complicated by the inherited aortopathy Loeys-Dietz syndrome.

BJOG : an international journal of obstetrics and gynaecology·2019
Same author

Randomized controlled trial of brain specific fatty acid supplementation in pregnant women increases brain volumes on MRI scans of their newborn infants.

Prostaglandins, leukotrienes, and essential fatty acids·2018
Same author

Location and orientation of lone pairs in apatite-type materials: a computational study.

Dalton transactions (Cambridge, England : 2003)·2017
Same author

Pregnancy in women with hypertrophic cardiomyopathy: data from the European Society of Cardiology initiated Registry of Pregnancy and Cardiac disease (ROPAC).

European heart journal·2017
Same author

Pregnancy, Marfan syndrome, and type-B aortic dissection.

BJOG : an international journal of obstetrics and gynaecology·2017

Area of Science:

  • Cardiology and Internal Medicine
  • Pharmacology and Therapeutics

Background:

  • Chronic heart failure (HF) is a growing public health concern, often leading to frequent hospitalizations.
  • While beta-blockers and ACE inhibitors improve mortality, significant challenges persist in managing HF exacerbations.
  • Current intravenous (IV) therapies for acute decompensated HF include inotropes, vasodilators, and diuretics, with high readmission rates.

Purpose of the Study:

  • To highlight the persistent challenges in managing acute decompensated heart failure (ADHF) exacerbations.
  • To underscore the lack of robust clinical trial data guiding intravenous inpatient therapy for HF.
  • To identify emerging therapeutic targets for ADHF management.

Main Methods:

  • Review of current therapeutic strategies for acute decompensated heart failure.

Related Experiment Videos

  • Analysis of hospitalization and readmission rates associated with HF exacerbations.
  • Discussion of existing and developmental intravenous agents for HF management.

    • Main Results:

    • Despite advances, hospitalizations for HF exacerbations are frequent, contributing significantly to healthcare burden.
    • Readmission rates for HF exacerbations remain high, ranging from 20% to 47% within six months.
    • No well-designed, randomized, placebo-controlled trials currently exist to guide intravenous inpatient therapy for HF exacerbations.

    Conclusions:

    • Significant gaps exist in the effective management of acute decompensated heart failure.
    • There is a critical need for evidence-based, randomized controlled trials to guide intravenous therapy for HF exacerbations.
    • Further research into novel agents like calcium sensitizers, vasopressin receptor antagonists, and natriuretic peptides is warranted.